Angiogenesis in the kidney: a new therapeutic target?

被引:45
|
作者
Lerman, Lilach O. [3 ,4 ]
Chade, Alejandro R. [1 ,2 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
[3] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
来源
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION | 2009年 / 18卷 / 02期
关键词
angiogenesis; kidney; microcirculation; vascular rarefaction; ENDOTHELIAL GROWTH-FACTOR; RENAL-ARTERY STENOSIS; GLOMERULAR CAPILLARY REPAIR; PROGENITOR CELLS; STEM-CELLS; EXPERIMENTAL HYPERCHOLESTEROLEMIA; INDUCED GLOMERULONEPHRITIS; IMPAIRED ANGIOGENESIS; RENOVASCULAR DISEASE; UNITED-STATES;
D O I
10.1097/MNH.0b013e32831ec1db
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review The prevalence of chronic kidney disease has been growing consistently for the past decades. Renal failure is often associated with defective angiogenesis, and recognition of the contribution of the renal microcirculation to the progression of chronic renal disease may aid in the development of therapeutic interventions. Recent findings Intra-renal proliferation, remodeling, and/or rarefaction of microvessels in response to injury can all aggravate nephron damage, and experimental evidence suggests that they may constitute the early steps in the complex pathways involved in progressive renal injury. Recent studies showed the benefits of targeted interventions deemed to promote neovascularization (e.g. progenitor cells, growth factors) on the ischemic myocardium and brain and in a few models of renal disease. Summary Evidence of aberrant renal microvascular architecture in various forms of renal disease provides the impetus to attempt modulating the renal microcirculation to interfere with the disease process. Targeted interventions to preserve the renal microcirculation may not only decrease the evolving injury in renal vascular disease but also potentially constitute a coadjuvant intervention to become part of a comprehensive management plan to improve the success of parallel strategies to preserve renal function, such as revascularization.
引用
收藏
页码:160 / 165
页数:6
相关论文
共 50 条
  • [21] Angiogenesis as a therapeutic target in urothelial carcinoma
    Pinto, Alvaro
    Redondo, Andres
    Zamora, Pilar
    Castelo, Beatriz
    Espinosa, Enrique
    ANTI-CANCER DRUGS, 2010, 21 (10) : 890 - 896
  • [22] Angiogenesis and arthritis: a potential therapeutic target?
    J Grosjean
    B Sivakumar
    E Paleolog
    Arthritis Res Ther, 6 (Suppl 3):
  • [23] Angiogenesis as a therapeutic target in breast cancer
    Koutras, Angelos K.
    Starakis, Ioannis
    Lymperatou, Dionysia
    Kalofonos, Haralabos P.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (12) : 1230 - 1238
  • [24] HuR: a promising therapeutic target for angiogenesis
    Dong, Rui
    Yang, Guo-Dong
    Luo, Nian-An
    Qu, Ya-Qi
    GLAND SURGERY, 2014, 3 (03) : 203 - 206
  • [25] Angiogenesis as a therapeutic target in urothelial carcinoma
    Sonpavde, Guru
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2016, 13 (06) : 306 - U22
  • [26] Angiogenesis as a Therapeutic Target in Malignant Gliomas
    Chi, Andrew S.
    Sorensen, A. Gregory
    Jain, Rakesh K.
    Batchelor, Tracy T.
    ONCOLOGIST, 2009, 14 (06): : 621 - 636
  • [27] Are epsins a therapeutic target for tumor angiogenesis?
    Klauber-DeMore, Nancy
    JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (12): : 4341 - 4343
  • [28] Angiogenesis as a therapeutic target in joint disease
    Paleolog, Ewa
    VASCULAR PHARMACOLOGY, 2012, 56 (5-6) : 324 - 324
  • [29] Adaptor protein is a new therapeutic target in chronic kidney disease
    Isaka, Yoshitaka
    KIDNEY INTERNATIONAL, 2017, 92 (06) : 1312 - 1314
  • [30] Is VEGF a new therapeutic target for hypertension in chronic kidney disease?
    Kim, Yon Su
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2013, 32 (02) : 49 - 51